[1] 黄仲义,肖永红,张 菁,等.万古霉素临床应用中国专家共识(2011)[J].中国新药与临床杂志,2011,30(8):561-573.
[2] Liu C,Bayer A,Cosgrove SE,et al.Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin resistant Staphylococcus aureus infections in adults and children[J].Clin Infect Dis,2011,52:e18-e55.
[3] Rybak M.Lomaestro B,Rotschafer JC,et al.Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American Society of Health-System Pharmacists,the Infectious Diseases Society of America,and the Society of Infectious Diseases Pharmacists[J].Am J Health Syst Pharm,2009,66:82-98.
[4] 中华医学会甲氧西林耐药金黄色葡萄球菌感染治疗策略专家组.中华医学会感染与抗微生物治疗策略高峰论坛:甲氧西林耐药金黄色葡萄球菌感染的治疗策略——专家共识[J].中国感染与化疗杂志,2011,11(6):401-416.
[5] Gilbert DN,Moellering RC,Eliopoulos MG,et al.The Sanford Guide to Antimicrobial Therapy 2010[M].40th ed.Sperryville,VA:Antimicrobial Therapy Inc,2010:25-27.
[6] Park KH,Kim ES,Kim HS,et al.Comparison of the clinical features,bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S.aureus[J].J Antimicrob Chemother,2012,67:1843-1849.
[7] Kullar R,Davis SL,Taylor TN,et al.Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort[J].Pharmacotherapy,2012,32:195-201.
[8] Sakoulas G,Gold HS,Cohen RA,et al.Effect of prolonged vancomycin administration on methillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia[J].J Antimicrob Chemother,2006,57:699-704.
[9] Thomson AH,Staatz CE,Tobin CM,et al.Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations[J].J Antimicrob Chemother 2009,63(5):1050-1057.
[10] Yoshida M, Yasuda N, Nishikata M,et al. New recommendations for vancomycin dosage for patients with MRSA pneumonia with various degrees of renal function impairment[J].J Infect Chemother, 2005, 11(4): 182-188.